Skip to main content
Top
Published in: Clinical Reviews in Allergy & Immunology 2-3/2010

01-04-2010

Intravenous Immunoglobulin in Lupus Panniculitis

Authors: João Espírito Santo, M. F. Gomes, M. J. Gomes, L. Peixoto, S. C. Pereira, A. Acabado, J. Freitas, G. Vinhas de Sousa

Published in: Clinical Reviews in Allergy & Immunology | Issue 2-3/2010

Login to get access

Abstract

Systemic lupus erythematosus (SLE) is a disease of unknown cause that may involve one or many organ or systems. Skin involvement is a major feature in this disease, and a wide variety of skin conditions may be present. Lupus erythematosus panniculitis (LEP) constitutes a rare form of cutaneous lupus characterized by recurrent nodular or plaque lesions that can vary from a benign and mild course to a more disfiguring disease. Initial therapy includes corticosteroids, antimalarials, and azathioprine and, in refractory cases, two antimalarials in association, mycophenolate mofetil, or other immunomodulators. Intravenous immuglobulin (IVIG) is used in many autoimmune disorders, like in SLE, although clinical trials have not yet taken place. In this report, we review skin manifestations of SLE and their treatment, IVIG, and finally a case of LEP successfully treated with IVIG when other therapy modalities failed.
Literature
1.
go back to reference Tan EM et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277CrossRefPubMed Tan EM et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277CrossRefPubMed
2.
go back to reference Ullrich SE (2000) Sun exposure and the lupus patient. Lupus Awareness 22:6–7 Ullrich SE (2000) Sun exposure and the lupus patient. Lupus Awareness 22:6–7
3.
go back to reference Vila LM, Mayor AM, Valentin AH et al (1999) Association of sunlight exposure and photoprotection measures with clinical outcome in systemic lupus erythematosus. Puerto Rico Health Sci J 18:89–94 Vila LM, Mayor AM, Valentin AH et al (1999) Association of sunlight exposure and photoprotection measures with clinical outcome in systemic lupus erythematosus. Puerto Rico Health Sci J 18:89–94
4.
go back to reference Doria A et al (1996) Photosensitivity in systemic lupus erythematosus: laboratory testing of ARA/ACR definition. Lupus 5:263–268CrossRefPubMed Doria A et al (1996) Photosensitivity in systemic lupus erythematosus: laboratory testing of ARA/ACR definition. Lupus 5:263–268CrossRefPubMed
5.
go back to reference Hochberg MC et al (1985) Systemic lupus erythematosus: a review of clinico-laboratory features and immunogenetic markers in 150 patients with emphasis on demographic subsets. Medicine 64:285–295CrossRefPubMed Hochberg MC et al (1985) Systemic lupus erythematosus: a review of clinico-laboratory features and immunogenetic markers in 150 patients with emphasis on demographic subsets. Medicine 64:285–295CrossRefPubMed
6.
go back to reference Mikle MF, Barton EN, Morgan OS, Deceulaer K (1996) Photosensitivity and antinuclear antibodies in black patients with systemic lupus erythematosus. J Assoc Acad Minor Phys 7:53–55 Mikle MF, Barton EN, Morgan OS, Deceulaer K (1996) Photosensitivity and antinuclear antibodies in black patients with systemic lupus erythematosus. J Assoc Acad Minor Phys 7:53–55
7.
go back to reference Sontheimer RD et al (1982) Serologic and HLA associations in subacute cutaneous lupus erythematosus, a clinical subset of lupus erythematosus. Ann Intern Med 97:664–671PubMed Sontheimer RD et al (1982) Serologic and HLA associations in subacute cutaneous lupus erythematosus, a clinical subset of lupus erythematosus. Ann Intern Med 97:664–671PubMed
8.
go back to reference Callen JP, Klein J (1988) Subacute cutaneous lupus erythematosus. Clinical, serologic, immunogenetic, and therapeutic considerations in seventy two patients. Arthritis Rheum 31:1007–1013CrossRefPubMed Callen JP, Klein J (1988) Subacute cutaneous lupus erythematosus. Clinical, serologic, immunogenetic, and therapeutic considerations in seventy two patients. Arthritis Rheum 31:1007–1013CrossRefPubMed
9.
go back to reference Herrero C et al (1988) Subacute cutaneous lupus erythematosus: clinicopathologic findings in thirteen cases. J Am Acad Dermatol 19:1057–1062CrossRefPubMed Herrero C et al (1988) Subacute cutaneous lupus erythematosus: clinicopathologic findings in thirteen cases. J Am Acad Dermatol 19:1057–1062CrossRefPubMed
10.
go back to reference Sontheimer RD, Provost TT (1996) Lupus erythematosus. In: Sontheimer RD, Provost TT (eds) Cutaneous manifestations of rheumatic diseases. Williams and Wilkins, Baltimore, pp 1–71 Sontheimer RD, Provost TT (1996) Lupus erythematosus. In: Sontheimer RD, Provost TT (eds) Cutaneous manifestations of rheumatic diseases. Williams and Wilkins, Baltimore, pp 1–71
11.
12.
go back to reference Provost TT (1979) Lupus band test. In: Beutner EH, Chorzelski TP, Bean SF (eds) Immunopathology of the skin, vol 22. Wiley, New York, pp 399–410 Provost TT (1979) Lupus band test. In: Beutner EH, Chorzelski TP, Bean SF (eds) Immunopathology of the skin, vol 22. Wiley, New York, pp 399–410
13.
go back to reference Burnham TK, Fine G (1971) The immunofluorescent “band” test for lupus erythematosus. III. Employing clinically normal skin. Arch Derm 103:24–32CrossRefPubMed Burnham TK, Fine G (1971) The immunofluorescent “band” test for lupus erythematosus. III. Employing clinically normal skin. Arch Derm 103:24–32CrossRefPubMed
14.
go back to reference Levy Y, Sherer Y, Ahmed A, Langevitz P, George J, Fabbrizzi F, Terryberry J, Meissner M, Lorber M, Peter JB, Shoenfeld Y (1999) A study of 20 SLE patients with intravenous immunoglobulin clinical and serologic response. Lupus 8:705CrossRefPubMed Levy Y, Sherer Y, Ahmed A, Langevitz P, George J, Fabbrizzi F, Terryberry J, Meissner M, Lorber M, Peter JB, Shoenfeld Y (1999) A study of 20 SLE patients with intravenous immunoglobulin clinical and serologic response. Lupus 8:705CrossRefPubMed
15.
go back to reference Strober BE (2001) Lupus panniculitis (lupus profundus). Dermatology Online Journal 7(2):20 New York University, Department of DermatologyPubMed Strober BE (2001) Lupus panniculitis (lupus profundus). Dermatology Online Journal 7(2):20 New York University, Department of DermatologyPubMed
16.
go back to reference Wimmershoff MB, Hohenleutner U, Landthaler M (2003) Discoid lupus erythematosus and lupus profundus in childhood: a report of two cases. Pediatr Dermatol 20:140–145PubMed Wimmershoff MB, Hohenleutner U, Landthaler M (2003) Discoid lupus erythematosus and lupus profundus in childhood: a report of two cases. Pediatr Dermatol 20:140–145PubMed
17.
go back to reference Bacanli A, Uzun S, Ciftcioglu MA, Alpsoy E (2005) A case of lupus erythematosus profundus with unusual manifestations. Lupus 14:403CrossRefPubMed Bacanli A, Uzun S, Ciftcioglu MA, Alpsoy E (2005) A case of lupus erythematosus profundus with unusual manifestations. Lupus 14:403CrossRefPubMed
18.
go back to reference Chen MT, Chen KS, Chen MJ et al (1999) Lupus profundus (panniculitis) in a chronic haemodialysis patient. Nephrol Dial Transplant 14:966–968CrossRefPubMed Chen MT, Chen KS, Chen MJ et al (1999) Lupus profundus (panniculitis) in a chronic haemodialysis patient. Nephrol Dial Transplant 14:966–968CrossRefPubMed
19.
go back to reference Martens PB, Moder KG, Ahmed I (1999) Lupus panniculitis: clinical perspectives from a case series. J Rheumatol 26:68–72PubMed Martens PB, Moder KG, Ahmed I (1999) Lupus panniculitis: clinical perspectives from a case series. J Rheumatol 26:68–72PubMed
20.
21.
go back to reference Watanabe T, Tsuchida T (1996) Lupus erythematosus profundus: a cutaneous marker for a distinct clinical subset? Br J Dermatol 134:123–125CrossRefPubMed Watanabe T, Tsuchida T (1996) Lupus erythematosus profundus: a cutaneous marker for a distinct clinical subset? Br J Dermatol 134:123–125CrossRefPubMed
22.
go back to reference Ng PP, Tan SH, Tan T (2002) Lupus erythematosus panniculitis: a clinicopathologic study. Int J Dermatol 41:488–490CrossRefPubMed Ng PP, Tan SH, Tan T (2002) Lupus erythematosus panniculitis: a clinicopathologic study. Int J Dermatol 41:488–490CrossRefPubMed
23.
24.
25.
go back to reference Holland NW, McKnight K, Challa VR et al (1995) Lupus panniculitis (profundus) involving the breast: report of 2 cases and review of the literature. J Rheumatol 22:344–346PubMed Holland NW, McKnight K, Challa VR et al (1995) Lupus panniculitis (profundus) involving the breast: report of 2 cases and review of the literature. J Rheumatol 22:344–346PubMed
26.
go back to reference White WL, Sherertz EF, Berg D et al (1993) Periparotid lupus erythematosus panniculitis: clinicopathologic correlation of two cases presenting as primary parotid disease. Arch Pathol Lab Med 117:535–539PubMed White WL, Sherertz EF, Berg D et al (1993) Periparotid lupus erythematosus panniculitis: clinicopathologic correlation of two cases presenting as primary parotid disease. Arch Pathol Lab Med 117:535–539PubMed
27.
go back to reference Ogura N, Fujisaku A, Jodo S et al (1997) Lupus erythematosus profundus around the salivary glands: a case resembling submandibular gland disease. Lupus 6:477–479CrossRefPubMed Ogura N, Fujisaku A, Jodo S et al (1997) Lupus erythematosus profundus around the salivary glands: a case resembling submandibular gland disease. Lupus 6:477–479CrossRefPubMed
28.
go back to reference Peters MS, Su WP (1989) Lupus erythematosus panniculitis. Med Clin North Am 73:1113–1126PubMed Peters MS, Su WP (1989) Lupus erythematosus panniculitis. Med Clin North Am 73:1113–1126PubMed
29.
go back to reference Laman SD, Provost TT (1994) Cutaneous manifestations of lupus erythematosus. Rheum Dis Clin North Am 13:641–644 Laman SD, Provost TT (1994) Cutaneous manifestations of lupus erythematosus. Rheum Dis Clin North Am 13:641–644
30.
go back to reference Tada J, Arata J, Katayama H (1991) Linear lupus erythematosus profundus in a child. J Am Acad Dermatol 24:871–874CrossRefPubMed Tada J, Arata J, Katayama H (1991) Linear lupus erythematosus profundus in a child. J Am Acad Dermatol 24:871–874CrossRefPubMed
31.
go back to reference Heid E (1998) A 17-year old Italian boy with a linear lupus erythematosus profundus. Eur J Dermatol 8:69PubMed Heid E (1998) A 17-year old Italian boy with a linear lupus erythematosus profundus. Eur J Dermatol 8:69PubMed
32.
go back to reference Stork J, Vosmik F (1994) Lupus erythematosus panniculitis with morphea-like lesions. Clin Exp Dermatol 19:79–82CrossRefPubMed Stork J, Vosmik F (1994) Lupus erythematosus panniculitis with morphea-like lesions. Clin Exp Dermatol 19:79–82CrossRefPubMed
33.
go back to reference Hytiroglou P, Phelps RG, Wattenberg DJ, Strauchen JA (1992) Cytophagic histiocytic panniculitis; molecular evidence for a clonal T cell disorder. J Am Acad Dermatol 27:333–336CrossRefPubMed Hytiroglou P, Phelps RG, Wattenberg DJ, Strauchen JA (1992) Cytophagic histiocytic panniculitis; molecular evidence for a clonal T cell disorder. J Am Acad Dermatol 27:333–336CrossRefPubMed
34.
go back to reference Saeki Y, Ohshima S, Kurimoto I, Miura H, Suemura M (2000) Maintaining remission of lupus erythematosus profundus (LEP) with cyclosporin A. Lupus 9:390CrossRefPubMed Saeki Y, Ohshima S, Kurimoto I, Miura H, Suemura M (2000) Maintaining remission of lupus erythematosus profundus (LEP) with cyclosporin A. Lupus 9:390CrossRefPubMed
35.
go back to reference Sanchez NP, Peters MS, Winkelmann RK (1981) The histopathology of lupus erythematosus panniculitis. J Am Acad Dermatol 5:673–680CrossRefPubMed Sanchez NP, Peters MS, Winkelmann RK (1981) The histopathology of lupus erythematosus panniculitis. J Am Acad Dermatol 5:673–680CrossRefPubMed
36.
go back to reference Lonceint J, Sassolas B, Lefur JM, Guillet G, Leroy JP (2001) Panniculitis and macrophage activation syndrome in a child with lupus erythematosus. Ann Dermatol Venereol 128:1339–1342 in FrenchPubMed Lonceint J, Sassolas B, Lefur JM, Guillet G, Leroy JP (2001) Panniculitis and macrophage activation syndrome in a child with lupus erythematosus. Ann Dermatol Venereol 128:1339–1342 in FrenchPubMed
38.
go back to reference Petri M (1996) Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus 5(Suppl 1):S16–S22CrossRefPubMed Petri M (1996) Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus 5(Suppl 1):S16–S22CrossRefPubMed
39.
go back to reference Khamashta MA, Wallace DJ (eds) (1996) Antimalarials in rheumatology. Lupus 5(Suppl 1):S1–S73. Khamashta MA, Wallace DJ (eds) (1996) Antimalarials in rheumatology. Lupus 5(Suppl 1):S1–S73.
40.
go back to reference Easterbrook M (1990) Is corneal deposition of antimalarial any indication of retinal toxicity? Can J Ophthalmol 25:249–251PubMed Easterbrook M (1990) Is corneal deposition of antimalarial any indication of retinal toxicity? Can J Ophthalmol 25:249–251PubMed
41.
go back to reference Mavrikakis M, Papazoglou S, Sifkakis PP, Vaiopoulos G, Rougas K (1996) Retinal toxicity in long term hydroxychloroquine treatment. Ann Rheum Dis 55:187–189CrossRefPubMed Mavrikakis M, Papazoglou S, Sifkakis PP, Vaiopoulos G, Rougas K (1996) Retinal toxicity in long term hydroxychloroquine treatment. Ann Rheum Dis 55:187–189CrossRefPubMed
42.
go back to reference Bienfang D, Coblyn JS, Liang MH, Corzillius M (2000) Hydroxychloroquine retinopathy despite regular ophthalmologic evaluation: a consecutive series. J Rheumatol 27:2703–2706PubMed Bienfang D, Coblyn JS, Liang MH, Corzillius M (2000) Hydroxychloroquine retinopathy despite regular ophthalmologic evaluation: a consecutive series. J Rheumatol 27:2703–2706PubMed
43.
go back to reference Yamada Y, Dekio S, Jidoi J, Ozasa S (1989) Lupus erythematosus profundus: report of a case treated with dapsone. J Dermatol 16:379–382PubMed Yamada Y, Dekio S, Jidoi J, Ozasa S (1989) Lupus erythematosus profundus: report of a case treated with dapsone. J Dermatol 16:379–382PubMed
44.
go back to reference Adu D, Cross J, Jayne DR (2001) Treatment of systemic lupus erythematosus with mycophenolate mofetil. Lupus 10:203–208CrossRefPubMed Adu D, Cross J, Jayne DR (2001) Treatment of systemic lupus erythematosus with mycophenolate mofetil. Lupus 10:203–208CrossRefPubMed
45.
go back to reference Gaubitz M, Schorat A, Schotte H, Kern P, Domschke W (1999) Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial. Lupus 8:731–736CrossRefPubMed Gaubitz M, Schorat A, Schotte H, Kern P, Domschke W (1999) Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial. Lupus 8:731–736CrossRefPubMed
46.
go back to reference Schanz S, Ulmer A, Rassner G, Fierlbeck G (2002) Successful treatment of subacute cutaneous lupus erythematosus with mycophenolate mofetil. Br J Dermatol 147:174–178CrossRefPubMed Schanz S, Ulmer A, Rassner G, Fierlbeck G (2002) Successful treatment of subacute cutaneous lupus erythematosus with mycophenolate mofetil. Br J Dermatol 147:174–178CrossRefPubMed
47.
go back to reference Goyal S, Nousari HC (2001) Treatment of resistant discoid lupus erythematosus of the palms and soles with mycophenolate mofetil. J Am Acad Dermatol 45:142–144CrossRefPubMed Goyal S, Nousari HC (2001) Treatment of resistant discoid lupus erythematosus of the palms and soles with mycophenolate mofetil. J Am Acad Dermatol 45:142–144CrossRefPubMed
48.
go back to reference Boehm I, Bieber T (2001) Chilblain lupus erythematosus Hutchinson: successful treatment with mycophenolate mofetil. Arch Dermatol 137:235–236PubMed Boehm I, Bieber T (2001) Chilblain lupus erythematosus Hutchinson: successful treatment with mycophenolate mofetil. Arch Dermatol 137:235–236PubMed
49.
go back to reference Knezevic-Maramica I, Kruskall MS (2003) Intravenous immune globulins: an update for clinicians. Transfusion 43:1460–1480CrossRefPubMed Knezevic-Maramica I, Kruskall MS (2003) Intravenous immune globulins: an update for clinicians. Transfusion 43:1460–1480CrossRefPubMed
50.
go back to reference Kazatchkine MD, Morell A (eds) (1996) Intravenous immunoglobulin research and therapy. Parthenon, New York Kazatchkine MD, Morell A (eds) (1996) Intravenous immunoglobulin research and therapy. Parthenon, New York
51.
go back to reference Imbach P, Barandun S, d’Apuzzo V et al (1981) High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1:1228–1231CrossRefPubMed Imbach P, Barandun S, d’Apuzzo V et al (1981) High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1:1228–1231CrossRefPubMed
52.
go back to reference Shoenfeld Y, Krause I (1996) Immunosuppression and immunomodulation of experimental models of systemic lupus erythematosus and antiphospholipid syndrome. Transplant Proc 28:3096–3098PubMed Shoenfeld Y, Krause I (1996) Immunosuppression and immunomodulation of experimental models of systemic lupus erythematosus and antiphospholipid syndrome. Transplant Proc 28:3096–3098PubMed
53.
go back to reference Darabi K, Abdel-Wahab O, Dzik WH (2006) Current usage of intravenous immune globulin and the rationale behind it: the Massachusetts General Hospital data and a review of the literature. Transfusion 46:741CrossRefPubMed Darabi K, Abdel-Wahab O, Dzik WH (2006) Current usage of intravenous immune globulin and the rationale behind it: the Massachusetts General Hospital data and a review of the literature. Transfusion 46:741CrossRefPubMed
54.
go back to reference Onouchi Z, Yanagisawa M, Hirayama T et al (1995) Optimal dosage and differences in therapeutic efficacy of IVIg in Kawasaki disease. Acta Paediatr Jpn 37:40–46PubMed Onouchi Z, Yanagisawa M, Hirayama T et al (1995) Optimal dosage and differences in therapeutic efficacy of IVIg in Kawasaki disease. Acta Paediatr Jpn 37:40–46PubMed
55.
go back to reference Samuelsson A, Towers TL, Ravetch JV (2001) Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291:484CrossRefPubMed Samuelsson A, Towers TL, Ravetch JV (2001) Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291:484CrossRefPubMed
56.
go back to reference Fehr J, Hoffman V, Kappeler U (1982) Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin. N Engl J Med 306:1254PubMed Fehr J, Hoffman V, Kappeler U (1982) Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin. N Engl J Med 306:1254PubMed
57.
go back to reference Tsubakio T, Kurata Y, Katagiri S et al (1983) Alteration of T cell subsets and immunoglobulin synthesis in vitro during high dose gamma globulin therapy in patients with idiopathic thrombocytopenic purpura. Clin Exp Immunol 53:697PubMed Tsubakio T, Kurata Y, Katagiri S et al (1983) Alteration of T cell subsets and immunoglobulin synthesis in vitro during high dose gamma globulin therapy in patients with idiopathic thrombocytopenic purpura. Clin Exp Immunol 53:697PubMed
58.
go back to reference Dietrich G, Kaveri SV, Kazatchkine MD (1992) Modulation of autoimmunity by intravenous immune globulin through interaction with the function of the immune/idiotypic network. Clin Immunol Immunopathol 62:S73CrossRefPubMed Dietrich G, Kaveri SV, Kazatchkine MD (1992) Modulation of autoimmunity by intravenous immune globulin through interaction with the function of the immune/idiotypic network. Clin Immunol Immunopathol 62:S73CrossRefPubMed
59.
go back to reference Kaveri SV, Dietrich G, Hurez V, Kazatchkine MD (1991) Intravenous immunoglobulins (IVIG) in the treatment of autoimmune diseases. Clin Exp Immunol 86:192PubMedCrossRef Kaveri SV, Dietrich G, Hurez V, Kazatchkine MD (1991) Intravenous immunoglobulins (IVIG) in the treatment of autoimmune diseases. Clin Exp Immunol 86:192PubMedCrossRef
60.
go back to reference Jayne DR, Davies MJ, Fox CJ et al (1991) Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet 337:1137CrossRefPubMed Jayne DR, Davies MJ, Fox CJ et al (1991) Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet 337:1137CrossRefPubMed
61.
go back to reference Palla R, Cirami C, Panichi V et al (1991) Intravenous immunoglobulin therapy of membranous nephropathy: Efficacy and safety. Clin Nephrol 35:98PubMed Palla R, Cirami C, Panichi V et al (1991) Intravenous immunoglobulin therapy of membranous nephropathy: Efficacy and safety. Clin Nephrol 35:98PubMed
62.
go back to reference Ashkenazi S, Cleary TG, Lopez E, Pickering LK (1988) Anticytotoxin neutralizing antibodies in immune globulin preparations: potential use in hemolytic–uremic syndrome. J Pediatr 113:1008CrossRefPubMed Ashkenazi S, Cleary TG, Lopez E, Pickering LK (1988) Anticytotoxin neutralizing antibodies in immune globulin preparations: potential use in hemolytic–uremic syndrome. J Pediatr 113:1008CrossRefPubMed
63.
go back to reference Bleeker WK, Teeling JL, Hack CE (2001) Accelerated autoantibody clearance by intravenous immunoglobulin therapy: studies in experimental models to determine the magnitude and time course of the effect. Blood 98:3136CrossRefPubMed Bleeker WK, Teeling JL, Hack CE (2001) Accelerated autoantibody clearance by intravenous immunoglobulin therapy: studies in experimental models to determine the magnitude and time course of the effect. Blood 98:3136CrossRefPubMed
64.
go back to reference Basta M, Van Goor F, Luccioli S et al (2003) F(ab)(2)-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins. Nat Med 9:431CrossRefPubMed Basta M, Van Goor F, Luccioli S et al (2003) F(ab)(2)-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins. Nat Med 9:431CrossRefPubMed
65.
go back to reference Sherer Y, Levy Y, Langevitz P, Rauova L, Fabrizzi F, Shoenfeld Y (2001) Adverse effects of intravenous immunoglobulin therapy in 56 patients with autoimmune diseases. Pharmacolgy 62:133–137 Sherer Y, Levy Y, Langevitz P, Rauova L, Fabrizzi F, Shoenfeld Y (2001) Adverse effects of intravenous immunoglobulin therapy in 56 patients with autoimmune diseases. Pharmacolgy 62:133–137
66.
go back to reference Rauova L, Lukac J, Levy Y, Rovensky J, Shoenfeld Y (2001) High-dose intravenous immunoglobulins for lupus nephritis—a salvage immunomodulation. Lupus 10:209–213CrossRefPubMed Rauova L, Lukac J, Levy Y, Rovensky J, Shoenfeld Y (2001) High-dose intravenous immunoglobulins for lupus nephritis—a salvage immunomodulation. Lupus 10:209–213CrossRefPubMed
67.
go back to reference Orbach H, Tishler M, Shoenfeld Y (2004) Intravenous immunoglobulin and the kidney—a two-edged sword. Semin Arthritis Rheum 34:593–601CrossRefPubMed Orbach H, Tishler M, Shoenfeld Y (2004) Intravenous immunoglobulin and the kidney—a two-edged sword. Semin Arthritis Rheum 34:593–601CrossRefPubMed
68.
go back to reference Pasatiempo AMG, Kroser JA, Rudnick M, Hoffmnann BI (1994) Acute renal failure after intravenous immunoglobulin therapy. J Rheumatol 21:347–349PubMed Pasatiempo AMG, Kroser JA, Rudnick M, Hoffmnann BI (1994) Acute renal failure after intravenous immunoglobulin therapy. J Rheumatol 21:347–349PubMed
69.
go back to reference Jordan SC (1989) Intravenous y-globulin therapy in systemic lupus erythematosus and immune complex disease. Ctin Immunol Immunopathol 53:164–169CrossRef Jordan SC (1989) Intravenous y-globulin therapy in systemic lupus erythematosus and immune complex disease. Ctin Immunol Immunopathol 53:164–169CrossRef
70.
go back to reference Hashkes PJ, Lovell DJ (1996) Vasculitis in systemic lupus erythematosus following intravenous immunoglobulin therapy. Clin Exp Rheumatol 14:673–675PubMed Hashkes PJ, Lovell DJ (1996) Vasculitis in systemic lupus erythematosus following intravenous immunoglobulin therapy. Clin Exp Rheumatol 14:673–675PubMed
71.
go back to reference Reinhart WH, Berchtold PE (1992) Effect of high-dose intravenous immunoglobulin therapy on blood rheology. Lancet 339:662–644CrossRefPubMed Reinhart WH, Berchtold PE (1992) Effect of high-dose intravenous immunoglobulin therapy on blood rheology. Lancet 339:662–644CrossRefPubMed
72.
go back to reference Dalakas MC (1994) High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology 44:223–226PubMed Dalakas MC (1994) High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology 44:223–226PubMed
73.
go back to reference Nishikawa M, Ichiyama T, Hasegawa M, Kawasaki K, Matsubara T, Furukawa S (2003) Safety from thromboembolism using intravenous immunoglobulin therapy in Kawasaki disease: study of whole-blood viscosity. Pediatr Int 45:156–158CrossRefPubMed Nishikawa M, Ichiyama T, Hasegawa M, Kawasaki K, Matsubara T, Furukawa S (2003) Safety from thromboembolism using intravenous immunoglobulin therapy in Kawasaki disease: study of whole-blood viscosity. Pediatr Int 45:156–158CrossRefPubMed
74.
go back to reference Woodruff RK, Grigg AP, Firkin FC, Smith IL (1986) Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients. Lancet 2:217–218CrossRefPubMed Woodruff RK, Grigg AP, Firkin FC, Smith IL (1986) Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients. Lancet 2:217–218CrossRefPubMed
75.
go back to reference Voltz R, Rosen FV, Yousry T, Beck J, Hohlfeld R (1996) Reversible encephalopathy with cerebral vasospasm in a Guillain–Barre syndrome patient treated with intravenous immunoglobulin. Neurology 46:250–251PubMed Voltz R, Rosen FV, Yousry T, Beck J, Hohlfeld R (1996) Reversible encephalopathy with cerebral vasospasm in a Guillain–Barre syndrome patient treated with intravenous immunoglobulin. Neurology 46:250–251PubMed
76.
go back to reference Sztajzel R, Le Floch-Rohr J, Eggimann P (1999) High-dose intravenous immunoglobulin treatment and cerebral vasospasm: a possible mechanism of ischemic encephalopathy? Eur Neurol 41:153–158CrossRefPubMed Sztajzel R, Le Floch-Rohr J, Eggimann P (1999) High-dose intravenous immunoglobulin treatment and cerebral vasospasm: a possible mechanism of ischemic encephalopathy? Eur Neurol 41:153–158CrossRefPubMed
77.
go back to reference Katz U, Shoenfeld Y (2005) Review: intravenous immunoglobulin therapy and thromboembolic complications. Lupus 14:802CrossRefPubMed Katz U, Shoenfeld Y (2005) Review: intravenous immunoglobulin therapy and thromboembolic complications. Lupus 14:802CrossRefPubMed
78.
go back to reference Go RS, Call TG (2000) Deep venous thrombosis of the arm after intravenous immunoglobulin infusion: case report and literature review of intravenous immunoglobulin-related thrombotic complications. Mayo Clin Proc 75:83–85CrossRefPubMed Go RS, Call TG (2000) Deep venous thrombosis of the arm after intravenous immunoglobulin infusion: case report and literature review of intravenous immunoglobulin-related thrombotic complications. Mayo Clin Proc 75:83–85CrossRefPubMed
79.
go back to reference Turner B, Wills AJ (2000) Cerebral infarction complicating intravenous immunoglobulin therapy in a patient with Miller Fisher syndrome. J Neurol Neurosurg Psychiatry 68:790–791CrossRefPubMed Turner B, Wills AJ (2000) Cerebral infarction complicating intravenous immunoglobulin therapy in a patient with Miller Fisher syndrome. J Neurol Neurosurg Psychiatry 68:790–791CrossRefPubMed
80.
go back to reference Shoenfeld Y, Krause I (2004) IVIG for autoimmune, fibrosis, and malignant conditions: our experience with 200 patients. J Clin Immunol 24:107–114CrossRefPubMed Shoenfeld Y, Krause I (2004) IVIG for autoimmune, fibrosis, and malignant conditions: our experience with 200 patients. J Clin Immunol 24:107–114CrossRefPubMed
82.
go back to reference Krause I, Blank M, Shoenfeld Y (1998) Anti-DNA and antiphospholipid antibodies in IVIg preparations: in vivo study in naive mice. J Clin Immunol 18:52–60CrossRefPubMed Krause I, Blank M, Shoenfeld Y (1998) Anti-DNA and antiphospholipid antibodies in IVIg preparations: in vivo study in naive mice. J Clin Immunol 18:52–60CrossRefPubMed
Metadata
Title
Intravenous Immunoglobulin in Lupus Panniculitis
Authors
João Espírito Santo
M. F. Gomes
M. J. Gomes
L. Peixoto
S. C. Pereira
A. Acabado
J. Freitas
G. Vinhas de Sousa
Publication date
01-04-2010
Publisher
Humana Press Inc
Published in
Clinical Reviews in Allergy & Immunology / Issue 2-3/2010
Print ISSN: 1080-0549
Electronic ISSN: 1559-0267
DOI
https://doi.org/10.1007/s12016-009-8162-x

Other articles of this Issue 2-3/2010

Clinical Reviews in Allergy & Immunology 2-3/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.